Oxcarbazepine (Trileptal) vs Rufinamide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Oxcarbazepine (Trileptal)
Marketed by Novartis
NCT00050934 · Phase 3 · completed
The study enrolled 132 participants and measured the clinical outcome of seizure-frequency change, but the registry does not document randomization, blinding, or a comparator arm. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
ClinicalTrials.gov records no allocation or masking for this study; the publication reports a randomized, rater-blind, parallel-group design.
Reported efficacy
change in seizure frequency/24 hours (during the last 72 hours in the Treatment Phase compared to Baseline): Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047. (met)
Result source: NCT00050934
Rufinamide
Marketed by Eisai and partners
NCT00334958 · Phase 3 · completed
This randomized, double-blind, placebo-controlled Phase 3 study gave adjunctive rufinamide 3,200 mg/day or placebo to adolescents and adults with refractory partial-onset seizures (357 randomized). Its single registered primary endpoint was the percentage change in total partial seizure frequency per 28 days. The median reduction was 23.25% with rufinamide and 9.80% with placebo, and the peer-reviewed paper reports p = 0.007, so the primary endpoint was met. The registry posts the same medians but no statistical test; the p-value comes from Biton et al., Epilepsia 2011.
The p-value comes from the peer-reviewed paper (Biton et al., Epilepsia 2011); ClinicalTrials.gov posts the medians with no statistical analysis.
Reported efficacy
Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase (Baseline, Days 13 to 96): Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis). (met)
Result source: NCT00334958
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Oxcarbazepine (Trileptal) | Rufinamide |
|---|---|---|
| Seizure frequency, % change | —Not posted · NCT00050934 | —Not reported |
| 50% responder rate | —Not posted · NCT00050934 | —Not reported |
| Seizure freedom | —Not posted · NCT00050934 | —Not reported |
Seizure frequency, % change
- Oxcarbazepine (Trileptal)
- —Not posted · NCT00050934
- Rufinamide
- —Not reported
50% responder rate
- Oxcarbazepine (Trileptal)
- —Not posted · NCT00050934
- Rufinamide
- —Not reported
Seizure freedom
- Oxcarbazepine (Trileptal)
- —Not posted · NCT00050934
- Rufinamide
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Oxcarbazepine (Trileptal): 4 of 4 rows · Rufinamide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Oxcarbazepine (Trileptal) | Rufinamide |
|---|---|---|
| Dropout rate | 14.6%a NCT00975715 · Phase 2/3 · combination show 5 more results—Group 1 (Inducers) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · combination —Group 2 (Neutral [Control]) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy 0% NCT00900237 · Phase 1 · registry result, not featured evidence —450 mg Bid NCT01679002 · Phase 1 · registry result, not featured evidence — NCT01678976 · Phase 1 · registry result, not featured evidence | 21%b NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3 show 3 more results13.8% NCT01146951 · Phase 3 · monotherapy 40% NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3 24.1% NCT01151540 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 12.5%a NCT00975715 · Phase 2/3 · combination show 5 more results—Group 1 (Inducers) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · combination —Group 2 (Neutral [Control]) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy — NCT00900237 · Phase 1 · registry result, not featured evidence —450 mg Bid NCT01679002 · Phase 1 · registry result, not featured evidence — NCT01678976 · Phase 1 · registry result, not featured evidence | 15.3%b NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3 show 3 more results13.8% NCT01146951 · Phase 3 · monotherapy 12% NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3 7.4% NCT01151540 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 2.1%a NCT00975715 · Phase 2/3 · combination show 5 more results0%Group 1 (Inducers) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · combination 0%Group 2 (Neutral [Control]) (FAS) NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy 0% NCT00900237 · Phase 1 · registry result, not featured evidence 0%450 mg Bid NCT01679002 · Phase 1 · registry result, not featured evidence 0% NCT01678976 · Phase 1 · registry result, not featured evidence | 3.4%b NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3 show 3 more results3.4% NCT01146951 · Phase 3 · monotherapy 40% NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3 16.7% NCT01151540 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | a somnolence 42.6% (placebo 9.8%) nasopharyngitis 10.6% (placebo 17.6%) vomiting 10.6% (placebo 5.9%) NCT00975715 · Phase 2/3 · combination show 5 more resultssomnolence 75% dizziness 56.3% headache 50% NCT03695094 · Phase 1 · registry result, not featured evidence · combination somnolence 80% dizziness 66.7% headache 60% NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy headache 100% dizziness 85.7% back pain 71.4% NCT00900237 · Phase 1 · registry result, not featured evidence 450 mg Bid dizziness 54.5% somnolence 54.5% frontal headache 18.2% NCT01679002 · Phase 1 · registry result, not featured evidence dizziness 23.1% headache 23.1% nodule subcutaneous 15.4% NCT01678976 · Phase 1 · registry result, not featured evidence | b dizziness 26.7% (placebo 8.3%) headache 16.5% (placebo 12.8%) fatigue 15.3% (placebo 10%) NCT00334958 · Phase 3 · monotherapy · Epilepsy · phase 3 show 3 more resultsnasopharyngitis 31% (placebo 30%) status epilepticus 27.6% (placebo 16.7%) decreased appetite 20.7% (placebo 6.7%) NCT01146951 · Phase 3 · monotherapy upper respiratory tract infection 28% vomiting 28% somnolence 20% NCT01405053 · Phase 3 · add on · Epilepsy, Lennox-Gastaut Syndrome · phase 3 nasopharyngitis 48.1% status epilepticus 40.7% somnolence 25.9% NCT01151540 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 2 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Rufinamide
+ 5 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Oxcarbazepine (Trileptal)'s landscape · Rufinamide's landscape